Article
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.
PloS one - 1 Jan 2017
Caspell-Garcia Chelsea, Simuni Tanya, Tosun-Turgut Duygu, Wu I-Wei, Zhang Yu, Nalls Mike, Singleton Andrew, Shaw Leslie A, Kang Ju-Hee, Trojanowski John Q, Siderowf Andrew, Coffey Christopher, Lasch Shirley, Aarsland Dag, Burn David, Chahine Lana M, Espay Alberto J, Foster Eric D, Hawkins Keith A, Litvan Irene, Richard Irene, Weintraub Daniel
Abstract excerpt
OBJECTIVES: To assess the neurobiological substrate of initial cognitive decline in Parkinson's disease (PD) to inform patient management, clinical trial design, and development of treatments. METHODS: We longitudinally assessed, up to 3 years, 423 newly diagnosed patients with idiopathic PD, untreated at baseline, from 33 international movement disorder centers. Study outcomes were four determinations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.